Clinical Study of the Effect and Safety of Combination of Deanxit with Siliankang in the Treatment for Students with Diarrhea-Predominant Irritable Bowel Syndrome

Objective:To observe the effect and safety of Deanxit in combination with Siliankang(Combined Bifidobacterium,Lactobacillus,Enterococcus and Bacillus cereus Tablets(Live),Oral) in treatment for students with diarrhea-predominant irritable bowel syndrome(D-IBS).Methods: 65 patients with refractory D-IBS were recruited into the randomized and open-label trial.According to patients'selection,30 patients with D-IBS(Rome Ⅱ criteria) were enrolled in a self-control study on combination of Deanxit with Siliankang therapy for 4 weeks,and 35 patients with D-IBS in a self-control study on the Siliankang therapy for 4 weeks.All patients were diagnosed and treated in the Erdos Central Hospital,between October 2007 and May 2009.Results: The total effective rate was 93.3% in combination treatment group,and 60.0% in control group.The total effective rate in combination treatment group was significantly higher than that of control group(P0.05).There were no obvious side-effects found in both groups.Conclusion: Deanxit combined with Siliankang is safe and effective in treatment of the students with DIBS.